The effects of parenteral prostacyclin therapy as add-on treatment to oral compounds in Eisenmenger syndrome
Sign Up to like & getrecommendations! Published in 2019 at "European Respiratory Journal"
DOI: 10.1183/13993003.01401-2019
Abstract: Pulmonary arterial hypertension (PAH) develops in 5–10% of patients with congenital heart disease (CHD) [1], and PAH associated with congenital heart disease (PAH-CHD) accounts for a significant proportion of PAH cases (34–42%) [2]. Eisenmenger syndrome… read more here.
Keywords: eisenmenger syndrome; effects parenteral; chd; therapy ... See more keywords